CABOTEGRAVIR
Page 1 of 1

N13
150

December 25, 2013

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-84) CABOTEGRAVIR

PRONUNCIATION kab" boe teg' ra vir

THERAPEUTIC CLAIM Treatment of HIV Infection; Prevention of HIV

Infection

CHEMICAL NAMES

1. Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, *N*-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3*S*,11a*R*)-

2. (3*S*,11a*R*)-*N*-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide

## STRUCTURAL FORMULA

MOLECULAR FORMULA C<sub>19</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>5</sub>

MOLECULAR WEIGHT 405.4

TRADEMARK None as yet

SPONSOR GlaxoSmithKline

CODE DESIGNATIONS GSK1265744A

CAS REGISTRY NUMBER 1051375-10-0

WHO NUMBER 9903

SCS